# Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial

> **NCT06128863** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Maria Sklodowska-Curie National Research Institute of Oncology** · enrollment: 40 (estimated)

## Conditions studied

- Neoadjuvant
- Immunotherapy
- Sarcoma,Soft Tissue
- Radiation Therapy

## Interventions

- **DRUG:** Pembrolizumab, Eftilagimod alfa

## Key facts

- **NCT ID:** NCT06128863
- **Lead sponsor:** Maria Sklodowska-Curie National Research Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-17
- **Primary completion:** 2025-04-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06128863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06128863, "Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06128863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*